stockrow
Saturday 7 November 2026
Export VANI’s income statement to Excel — free account
Vivani Medical, Inc.
VANI Healthcare Biotechnology
- EPS
- +41.7%
- Free cash flow
- +0.39%
Quarter to June 2026, against a year earlier
1.06
0.02
+1.92%
Follow VANI
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 4 | 8 | 7 | 3 | — | — | — | — | — | — | 3 | (5.4%) | — | — | — | — | |
| Gross margin, % | (152.85) | 35.75 | 29.12 | 36.31 | 0.00 | 0.00 | — | — | — | — | 0.00 | +152.9 pt | ||||||
| EBT | (33) | (29) | (35) | (34) | (15) | (13) | (14) | (26) | (23) | (27) | (26) | (2.4%) | ||||||
| EBT margin, % | (832.60) | (358.06) | (508.90) | (994.14) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +832.6 pt | ||||||
| Net income | (33) | (29) | (35) | (34) | (15) | (13) | (14) | (26) | (23) | (27) | (26) | (2.4%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 2.42 | 3.53 | 2.49 | 0.69 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (20.16) | (12.72) | (12.72) | (6.84) | (2.10) | (0.39) | (0.36) | (0.50) | (0.43) | (0.43) | (0.35) | (34.8%) | ||||||
| Cash flow | (15.21) | (10.61) | (10.78) | (5.64) | (2.45) | (0.33) | (0.49) | (0.47) | (0.38) | (0.39) | (0.29) | (33.4%) | ||||||
| Capex | (0.30) | (0.12) | (0.06) | (0.10) | 0.01 | (0.02) | (0.01) | (0.02) | (0.01) | (0.02) | (0.01) | (26.4%) | ||||||
| Free cash flow | (15.51) | (10.73) | (10.84) | (5.74) | (2.44) | (0.35) | (0.50) | (0.48) | (0.39) | (0.41) | (0.30) | (33.2%) | ||||||
| Book value | 6.77 | 3.49 | 1.12 | 1.48 | (0.10) | 0.07 | 1.16 | 0.41 | 0.32 | 0.25 | 0.22 | (30.6%) | ||||||
| Shares, m | 2 | 2 | 3 | 5 | 7 | 33 | 38 | 51 | 55 | 62 | 73 | +49.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | 19.55 | 13.67 | 8.52 | 25.84 | — | — | — | — | — | — | 27.32 | 16.9 | ||||||
| P/B | 6.99 | 13.81 | 19.05 | 12.00 | — | — | — | — | — | — | 4.87 | 13.0 | ||||||
| EV/Sales | 16.82 | 12.68 | 7.87 | 22.56 | — | — | — | — | — | — | 22.08 | 15.0 | ||||||
| EV/FCF | (2.62) | (4.17) | (1.81) | (2.71) | — | — | — | — | — | — | (2.82) | (2.8) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (25) | (24) | (30) | (28) | (17) | (11) | (19) | (24) | (21) | (24) | (25) | (0.3%) | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | (1) | 0 | (1) | (1) | (1) | (1) | +10.2% | ||||||
| Free cash flow | (26) | (24) | (30) | (28) | (17) | (12) | (19) | (25) | (21) | (25) | (26) | 0.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 10 | 7 | 2 | 6 | (1) | 0 | 41 | 17 | 14 | 11 | 15 | +1.8% | |||||
| Net debt | (11) | (8) | (4) | (11) | (1) | (2) | (45) | (21) | (18) | (16) | (20) | +4.6% | ||||||
| Shareholders’ equity | 11 | 8 | 3 | 7 | (1) | 2 | 44 | 21 | 18 | 16 | 19 | +3.9% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (147.28) | (182.17) | (278.76) | (246.27) | (141.32) | (257.70) | (49.09) | (52.93) | (53.77) | (65.74) | (74.60) | +81.5 pt | |||||
| ROIC | (7,603.02) | (41,582.85) | 0.00 | 0.00 | 0.00 | (2,901.35) | 0.00 | (15,750.58) | 0.00 | 0.00 | 0.00 | +7,603.0 pt | ||||||
| ROE | (211.26) | (299.70) | (640.05) | (648.56) | (450.70) | (1,424.76) | (59.39) | (78.85) | (122.42) | (159.62) | (220.40) | +51.6 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 110 | 112 | 123 | 112 | 12 | 15 | 50 | 44 | 36 | 36 | — | (11.7%) | |||||
| Revenue/emp, $m | 0.04 | 0.07 | 0.06 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2019 · latest quarter Dec 2019
Vivani Medical, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| UNCY Unicycive Therapeutics, Inc. | $96.9M | — (loss-making) | — (loss-making) | — | n/m | +9.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PMVP PMV Pharmaceuticals, Inc. | $96.3M | — (loss-making) | — | — | n/m | +20.27% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BDTX Black Diamond Therapeutics, Inc. | $95.4M | — (loss-making) | — (loss-making) | — | n/m | +12.91% (above 0%: growing) | 100.00% | 0.00% | Compare |
| LENZ LENZ Therapeutics, Inc. | $94.6M | — (loss-making) | — (loss-making) | −72.93% (below 0%: shrinking) | n/m | −147.16% (below 0%: shrinking) | 86.58% | (972.75%) | Compare |
| VANI Vivani Medical, Inc. | $93.8M | — (loss-making) | — (loss-making) | −71.87% (below 0%: shrinking) | n/m | +0.39% (above 0%: growing) | 0.00% | 0.00% | |
| VXRT VAXART, INC. | $92.4M | 2.8× | — (loss-making) | −85.33% (below 0%: shrinking) | n/m | −57.23% (below 0%: shrinking) | 100.00% | (162.74%) | Compare |
| NMRA Neumora Therapeutics, Inc. | $91.5M | — (loss-making) | — | — | n/m | +24.45% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ICCC ImmuCell Corporation | $90.4M | 117× | — (loss-making) | +11.50% (above 0%: growing) | +233.33% (above 0%: growing) | +54.86% (above 0%: growing) | 33.92% | 26.93% | Compare |
| SEER Seer, Inc. | $90.3M | — (loss-making) | — (loss-making) | −23.43% (below 0%: shrinking) | n/m | +36.73% (above 0%: growing) | 48.55% | (542.91%) | Compare |
| Median of peers | $93.5M | — | — | −48.18% | — | +16.59% | 41.24% | 0.00% |
Pay and ownership Proxy statement filed 29 April 2026
Ownership
Directors and executive officers, together
53.30%
Gregg Williams
46.00%
Joachim Bolck
6.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement